vs
ANI PHARMACEUTICALS INC（ANIP）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是ROGERS CORP的1.2倍（$247.1M vs $200.5M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 2.2%，领先8.9%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 5.2%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $1.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs -3.3%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
ANIP vs ROG — 直观对比
营收规模更大
ANIP
是对方的1.2倍
$200.5M
营收增速更快
ANIP
高出24.4%
5.2%
净利率更高
ANIP
高出8.9%
2.2%
自由现金流更多
ANIP
多$28.0M
$1.1M
两年增速更快
ANIP
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $200.5M |
| 净利润 | $27.5M | $4.5M |
| 毛利率 | — | 32.2% |
| 营业利润率 | 14.1% | — |
| 净利率 | 11.1% | 2.2% |
| 营收同比 | 29.6% | 5.2% |
| 净利润同比 | 367.5% | 421.4% |
| 每股收益（稀释后） | $1.14 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $247.1M | $201.5M | ||
| Q3 25 | $227.8M | $216.0M | ||
| Q2 25 | $211.4M | $202.8M | ||
| Q1 25 | $197.1M | $190.5M | ||
| Q4 24 | $190.6M | $192.2M | ||
| Q3 24 | $148.3M | $210.3M | ||
| Q2 24 | $138.0M | $214.2M |
净利润ANIPROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $27.5M | $4.6M | ||
| Q3 25 | $26.6M | $8.6M | ||
| Q2 25 | $8.5M | $-73.6M | ||
| Q1 25 | $15.7M | $-1.4M | ||
| Q4 24 | $-10.3M | $-500.0K | ||
| Q3 24 | $-24.2M | $10.7M | ||
| Q2 24 | $-2.3M | $8.1M |
毛利率ANIPROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
营业利润率ANIPROG
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 3.5% | ||
| Q3 25 | 15.9% | 7.3% | ||
| Q2 25 | 6.6% | -33.3% | ||
| Q1 25 | 13.3% | -0.2% | ||
| Q4 24 | -2.3% | -6.6% | ||
| Q3 24 | -13.8% | 6.9% | ||
| Q2 24 | 3.7% | 5.3% |
净利率ANIPROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 11.1% | 2.3% | ||
| Q3 25 | 11.7% | 4.0% | ||
| Q2 25 | 4.0% | -36.3% | ||
| Q1 25 | 8.0% | -0.7% | ||
| Q4 24 | -5.4% | -0.3% | ||
| Q3 24 | -16.3% | 5.1% | ||
| Q2 24 | -1.7% | 3.8% |
每股收益（稀释后）ANIPROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $1.14 | $0.20 | ||
| Q3 25 | $1.13 | $0.48 | ||
| Q2 25 | $0.36 | $-4.00 | ||
| Q1 25 | $0.69 | $-0.08 | ||
| Q4 24 | $-0.45 | $-0.04 | ||
| Q3 24 | $-1.27 | $0.58 | ||
| Q2 24 | $-0.14 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $1.2B |
| 总资产 | $1.4B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $285.6M | $197.0M | ||
| Q3 25 | $262.6M | $167.8M | ||
| Q2 25 | $217.8M | $157.2M | ||
| Q1 25 | $149.8M | $175.6M | ||
| Q4 24 | $144.9M | $159.8M | ||
| Q3 24 | $145.0M | $146.4M | ||
| Q2 24 | $240.1M | $119.9M |
股东权益ANIPROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $540.7M | $1.2B | ||
| Q3 25 | $505.8M | $1.2B | ||
| Q2 25 | $436.8M | $1.2B | ||
| Q1 25 | $418.6M | $1.3B | ||
| Q4 24 | $403.7M | $1.3B | ||
| Q3 24 | $405.9M | $1.3B | ||
| Q2 24 | $455.8M | $1.3B |
总资产ANIPROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $920.8M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $1.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 0.5% |
| 资本支出强度资本支出/营收 | 0.5% | 2.3% |
| 现金转化率经营现金流/净利润 | 1.10× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $70.1M |
8季度趋势，按日历期对齐
经营现金流ANIPROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $30.4M | $46.9M | ||
| Q3 25 | $44.1M | $28.9M | ||
| Q2 25 | $75.8M | $13.7M | ||
| Q1 25 | $35.0M | $11.7M | ||
| Q4 24 | $15.9M | $33.7M | ||
| Q3 24 | $12.5M | $42.4M | ||
| Q2 24 | $17.4M | $22.9M |
自由现金流ANIPROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $29.1M | $42.2M | ||
| Q3 25 | $38.0M | $21.2M | ||
| Q2 25 | $71.8M | $5.6M | ||
| Q1 25 | $32.5M | $2.1M | ||
| Q4 24 | $13.5M | $18.3M | ||
| Q3 24 | $7.7M | $25.2M | ||
| Q2 24 | $13.0M | $8.8M |
自由现金流率ANIPROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 11.8% | 20.9% | ||
| Q3 25 | 16.7% | 9.8% | ||
| Q2 25 | 34.0% | 2.8% | ||
| Q1 25 | 16.5% | 1.1% | ||
| Q4 24 | 7.1% | 9.5% | ||
| Q3 24 | 5.2% | 12.0% | ||
| Q2 24 | 9.4% | 4.1% |
资本支出强度ANIPROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.5% | 2.3% | ||
| Q3 25 | 2.7% | 3.6% | ||
| Q2 25 | 1.9% | 4.0% | ||
| Q1 25 | 1.3% | 5.0% | ||
| Q4 24 | 1.3% | 8.0% | ||
| Q3 24 | 3.2% | 8.2% | ||
| Q2 24 | 3.2% | 6.6% |
现金转化率ANIPROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 1.10× | 10.20× | ||
| Q3 25 | 1.66× | 3.36× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ROG
暂无分部数据
